DRDO Releases Instructions For Using Anti-Covid 2-DG Drug, Health News, ET HealthWorld
The drug can be administered to patients under the care and prescription of doctors, since it has published instructions for its use.
“Ideally, 2DG should be prescribed as soon as possible by physicians for moderate to severe Covid patients for up to 10 days,” DRDO said in a statement.
The first batch of anti-Covid drug developed by DRDO was launched last month to treat patients with the deadly disease.
The medicine is in powder form and can be taken with water.
The DRDO said patients with uncontrolled diabetes, severe heart problems, acute respiratory distress syndrome (ARDS), severe liver and kidney failure have yet to be studied, so they should exercise caution. .
The anti-Covid drug should not be given to pregnant and breastfeeding women and patients under the age of 18, he said.
The drug could be a game-changer in the fight against the pandemic, as it helps speed recovery for hospital patients and reduces dependence on oxygen.
The results of clinical trials have shown that the drug helps speed recovery in hospitalized patients and reduces dependence on supplemental oxygen. A higher proportion of patients treated with 2-DG showed negative RT-PCR conversion in Covid patients.
The drug was found to be safe for Covid-19 patients in phase 2 trials, conducted between May and October of last year. It has been shown to be effective in shortening hospital stays for Covid patients and reducing their dependence on supplemental oxygen.
During the first wave of the pandemic in April last year, scientists at INMAS-DRDO conducted laboratory experiments with help from the Center for Cellular and Molecular Biology (CCMB), Hyderabad, and discovered that this molecule acts effectively against SARS-CoV-2. virus and inhibits viral growth.